Surrozen, Inc. (SRZNW)

Surrozen, Inc. (SRZNW) — VMCI valuation read

SRZNW screens at VMCI 36/100, a 14-point gap below the Healthcare sector median (50). For a mid-cap Surrozen, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SRZNW has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SRZNW trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.8x leaves covenant headroom, which sets the rate-cycle exposure for Surrozen, Inc..

SRZNW rose 2.5% over the trailing 7 days, with a +6.4% read on a 30-day basis.